Novo contributed to the right track of the largest monthly decline since 2002, the investor’s concerns grow

Written by Maggie Vic and Lucy Ritano

LONDON (Reuters) -Novo Nordisk shares have decreased by 25 % so far in March, and they are on the right path to the largest monthly decrease since July 2002, as the investor fears that the pioneer of the drug market in obesity has lost its rival to its American rival Eli Lily.

The launch of the Danish drugs pushed him to inject weight loss into Wegovy to become the most companies in Europe through the market value in September 2023, a cloak it lost on Monday in front of the German software company SAP, although the French luxury LVMH group has also canceled it shortly.

Novo was pressured last year to demonstrate that it could maintain its interest in the profitable obesity market after its opponent in the United States fired Zepbound, which led in clinical trials to lose weight greater than Wegovy.

This did not happen, for example, says investors and analysts who quickly monitor market morale towards Novo, although sales of Wagofi have multiplied in the fourth quarter of last year.

Since last summer, Novo has lost half its market value, and the shares have decreased by 23 % so far this year. The stocks rise in 6 % night this year.

Alexander Jenk, the wallet manager at the German company “Wegovy”, said that the feelings of the stock have become very negative, as it is widely acceptable that Wegoz from Novo is much lower than Zepbound’s Lilly.

Investors and analysts see a greater cause of anxiety in prescription data in the US weekly, which has been watched closely for Wegovy and Zepbound.

American doctors for most 2024 described Wegovy or Zepbound based on what was available in display restrictions.

In the quarterly profits in February, Novo said it increased the supply of Wegovy in the United States market and said its financial guidelines reflect this.

Instead, Total Weight Prescyys remained flat for more than a month, according to IQVia data published by analysts. The data showed that the Zepbound prescriptions outperformed Wegovy by 80,000 per week ending on March 14.

Lucas Liu, director of funds in asset management that focuses on health care in Switzerland, which carries the shares of Novo, said that other investors “run out of patience” said that the text programs that were not fluctuated by Wipofi.

This comes in the aftermath of data from two trials from the next generation of Cagrisema, which was released in December and early March, which are also less than expectations.

“The terrible follow -up in the second quarter of 2025 at a disappointment end until 2024,” Nordnet Per Hansen analyst told Reuters on Thursday.

Emily Field, Barclays analyst, said the exacerbation of pain was the threat of definitions in the United States.

Field said that the pressure on Novo is especially high because it produces its active ingredient for Wegovy and Diabets DRGOMPIC in Denmark.

The President of Novo Helg Lund referred to the stock prices for the annual general meeting on Thursday. He said that the company’s long -term strategy is clear. “We are still committed to the implementation of this strategy with transparency communication about our progress.”

(I participated in the reports of Maggie Fikk and Ludy Raitanawwaditional by Stine Jacobsen in Copenhagen and Greta Rosen Fondan in Gdansk; edited by David Evans)